Enfortumab Vedotin−Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma

Among patients with advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV), is development of EV-induced cutaneous adverse events (cAEs) associated with improved survival, and how does this association compare with cutaneous immune-related adverse events (cirAEs)? This multi-institutional retrospective cohort study of 449 participants found that EV-induced cAEs were associated with significantly improved progression-free survival (hazard ratio, 0.60; 95% CI, 0.31-0.67;   < .001) and overall survival (hazard ratio, 0.46; 95% CI, 0.31-0.67;   < .001) across landmark analyses. These findings suggest that EV-induced cAEs are independently associated with improved survival in patients, suggesting potential prognostic value during treatment of advanced urothelial cancer.

Corresponding Author: Yevgeniy R. Semenov, MD, MA, Department of Dermatology, Massachusetts General Hospital, 40 Blossom St, Bartlett Hall 6R, Room 626, Boston, MA 02115 (ysemenov@mgh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.